Dee Datta is the Chief Executive Officer and a co-founder of Switch Therapeutics, an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs.Prior to Switch, Dee served as Chief Business Officer at XOMA and Vice President of Corporate Development at Forty Seven Inc. Dee holds a Ph.D. in Biochemistry and Molecular Biophysics from Caltech and MBA from Stanford University.